Changes in growth hormone-binding protein in girls with central precocious puberty treated with a depot preparation of luteinizing hormone-releasing hormone analogue.
Growth hormone-binding protein (GHBP) was studied in 11 girls with true precocious puberty, aged 7.3 +/- 0.2 years (mean +/- SE), before and after the first 6 months of treatment with luteinizing hormone-releasing hormone analogue D-Trp6-LHRH. The 125I-human GH was incubated with 150 microliters of serum, bound and free GH were separated by gel filtration. The levels of GHBP increased significantly from 24.2 +/- 1.3 to 28.1 +/- 1.9% (p < 0.002, paired t test), more than expected for the normal age-dependent increase. The efficiency of LHRH-A therapy was confirmed by a decrease in growth rate and normalization of clinical and biological parameters. Our data agree with the hypothesis that the pubertal spurt is mediated by a sex-steroid-induced rise in GH concentration, and they suggest that the levels of GHBP may be related to the GH secretion and its variation with treatment.
Oliveira
S B
SB
Service d'Endocrinologie Pédiatrique, Hôpital St-Vincent-de-Paul, Paris, France.
Donnadieu
M
M
Chaussain
J L
JL
D002352:Carrier Proteins / Q000097:blood*; D002648:Child; D003692:Delayed-Action Preparations; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011629:Puberty, Precocious / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000627:therapeutic use*
D002352:Carrier Proteins; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; C051815:somatotropin-binding protein